Ardsley Advisory Partners LP Adverum Biotechnologies, Inc. Transaction History

Ardsley Advisory Partners LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 14, 2019	SELL	$2.87 - $5.92 $315,700 - $651,200	-110,000 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$5.3 - $6.9 $53,000 - $69,000	10,000 Added 10.0%	110,000 $583,000
Q4 2017 Feb 14, 2018	BUY	$2.85 - $3.95 $285,000 - $395,000	100,000	100,000 $350,000

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $681M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Ardsley Advisory Partners LP, based on Form 13F filings with the SEC.

Stay updated on Ardsley Advisory Partners LP with notifications on news.